These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Drug Distribution to Human Tissues: Prediction and Examination of the Basic Assumption in In Vivo Pharmacokinetics-Pharmacodynamics (PK/PD) Research. Poulin P J Pharm Sci; 2015 Jun; 104(6):2110-2118. PubMed ID: 25808270 [TBL] [Abstract][Full Text] [Related]
12. Indirect pharmacodynamic response models do not require any parametric pharmacokinetic model to be fitted to effect-time data. Piotrovsky VK Methods Find Exp Clin Pharmacol; 1997 Dec; 19(10):723-9. PubMed ID: 9542723 [TBL] [Abstract][Full Text] [Related]
13. Quantitative pharmacology or pharmacokinetic pharmacodynamic integration should be a vital component in integrative pharmacology. Gabrielsson J; Green AR J Pharmacol Exp Ther; 2009 Dec; 331(3):767-74. PubMed ID: 19779129 [TBL] [Abstract][Full Text] [Related]
14. Translational PK/PD modeling for cardiovascular safety assessment of drug candidates: Methods and examples in drug development. Caruso A; Frances N; Meille C; Greiter-Wilke A; Hillebrecht A; Lavé T J Pharmacol Toxicol Methods; 2014; 70(1):73-85. PubMed ID: 24879942 [TBL] [Abstract][Full Text] [Related]
15. A two-dimensional mathematical model of non-linear dual-sorption of percutaneous drug absorption. George K Biomed Eng Online; 2005 Jul; 4():40. PubMed ID: 15992411 [TBL] [Abstract][Full Text] [Related]
16. A paradigm shift in pharmacokinetic-pharmacodynamic (PKPD) modeling: rule of thumb for estimating free drug level in tissue compared with plasma to guide drug design. Poulin P J Pharm Sci; 2015 Jul; 104(7):2359-68. PubMed ID: 25943586 [TBL] [Abstract][Full Text] [Related]
17. Nociceptive stimulus modality-related difference in pharmacokinetic-pharmacodynamic modeling of morphine in the rat. Shang GW; Liu DN; Yan LH; Cui XY; Zhang KP; Qi C; Chen J Pharmacol Biochem Behav; 2006 Oct; 85(2):464-73. PubMed ID: 17126387 [TBL] [Abstract][Full Text] [Related]
18. Modelling response time profiles in the absence of drug concentrations: definition and performance evaluation of the K-PD model. Jacqmin P; Snoeck E; van Schaick EA; Gieschke R; Pillai P; Steimer JL; Girard P J Pharmacokinet Pharmacodyn; 2007 Feb; 34(1):57-85. PubMed ID: 17051439 [TBL] [Abstract][Full Text] [Related]
19. Comparison of different pharmacodynamic models for PK-PD modeling of verapamil in renovascular hypertension. Bertera FM; Mayer MA; Opezzo JA; Taira CA; Höcht C J Pharmacol Toxicol Methods; 2008; 57(3):212-9. PubMed ID: 18442930 [TBL] [Abstract][Full Text] [Related]